NTLA Intellia Therapeutics
- 21.980
- +1.220+5.88%
Intellia Therapeutics News
Intellia Therapeutics Announced The Acceptance Of An Oral Presentation From The Phase 1 Portion Of The Ongoing NTLA-2002 Phase 1/2 Study At The European Academy Of Allergy And Clinical Immunology Congress 2024
Intellia Therapeutics Announced The Acceptance Of An Oral Presentation From The Phase 1 Portion Of The Ongoing NTLA-2002 Phase 1/2 Study At The European Academy Of Allergy And Clinical Immunology Cong
Institutional Owners May Consider Drastic Measures as Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Recent US$125m Drop Adds to Long-term Losses
Key Insights Significantly high institutional ownership implies Intellia Therapeutics' stock price is sensitive to their trading actions The top 11 shareholders own 50% of the company Recent sale
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $29 Price Target
Wedbush analyst David Nierengarten reiterates Intellia Therapeutics with a Neutral and maintains $29 price target.
Intellia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 31.1% Wedbush → $29 Reiterates Neutral → Neutral 02/23/2024 44.67% Goldman Sachs → $32 Downgrad
Intellia Therapeutics Welcomes New Principal Accounting Officer
2 Stocks Down 30% to Buy Right Now
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)
Intellia Therapeutics (NASDAQ:NTLA Shareholders Incur Further Losses as Stock Declines 9.9% This Week, Taking Three-year Losses to 65%
Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?
Shareholders in Intellia Therapeutics (NASDAQ:NTLA) Are in the Red If They Invested Three Years Ago
Investing in stocks inevitably means buying into some companies that perform poorly. But long term Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders have had a particularly rough ride in the las
Better Cathie Wood Stock: Moderna Vs. Intellia
Update: Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals
(Updates with Regeneron's response in the third paragraph and the latest stock move of Intellia and Regeneron in the fifth paragraph.) Intellia Therapeutics (NTLA) said in a Friday filing that it has
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals
Intellia Therapeutics (NTLA) said in a Friday filing that it has decided to end its 2020 agreement with Regeneron Pharmaceuticals (REGN) on developing gene editing products directed to factor IX, a bl
Intellia Opts Out of Hemophilia Pact With Regeneron
Intellia Therapeutics On March 19, Notified Regeneron Pharmaceuticals That Co Is Opting Out Of Its Factor IX Co-Development And Co-Funding Agreement
Intellia Therapeutics On March 19, Notified Regeneron Pharmaceuticals That Co Is Opting Out Of Its Factor IX Co-Development And Co-Funding Agreement
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis With Cardiomyopathy
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today
Is Intellia Therapeutics Stock a Buy Now?
Analysis
Price Target
No Data
